H.R. 597 · 117th Congress
Pandemic Treatment Access and Affordability Act of 2021
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 117th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
SchakowskySponsor26 cosponsors · 26 D
D
Bishop
JC
D
Chu
PD
D
DeFazio
RD
D
DeLauro
LD
D
Doggett
RG
D
Grijalva
PJ
D
Jayapal
RK
D
Khanna
BM
D
McCollum
EN
D
Norton
CP
D
Pingree
MP
D
Pocan
JR
D
Raskin
PW
D
Welch
AC
D
Carson
MD
D
DeSaulnier
DE
D
Evans
AH
D
Hastings
MS
D
San Nicolas
AL
D
Lawson
MS
D
Scanlon
DT
D
Titus
SC
D
Cohen
JH
D
Hayes
DP
D
Price
BT
D
Thompson14 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies.
What it does: CRS summary · Introduced in House · Jan 28, 2021
Pandemic Treatment Access and Affordability Act of 2021
This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies.
With respect to a COVID-19 drug patent developed using certain types of federal support, any license granted by the federal government shall be open and nonexclusive. Similarly, a licensee or assignee for such a patent shall grant open nonexclusive licenses for the patent. An entity that receives a license shall pay reasonable royalties to (1) the patent holder, or (2) the owner of marketing exclusivity rights granted by the Food and Drug Administration (FDA) that were terminated under this bill.
The bill requires that such drugs be offered at a fair and reasonable price based on certain considerations, such as access.
If the Department of Health and Human Services (HHS) finds that the price of any drug to address a public health emergency is excessive, HHS must void any FDA-granted exclusivity for the drug and grant open and nonexclusive licenses to other manufacturers. Such licenses are subject to reasonable royalty requirements.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Pandemic Treatment Access and Affordability Act of 2021
Latest action (Mar 22, 2021): Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
Policy area: Health · Origin: House · Introduced: Jan 28, 2021
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.